Welcome to our dedicated page for Haemonetics Corporation news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Corporation stock.
Haemonetics Corporation (NYSE: HAE) is a global leader in blood management solutions, dedicated to improving patient care and reducing healthcare costs. The company offers a comprehensive portfolio of integrated devices, information management systems, and consulting services that address every facet of blood and plasma management. Haemonetics operates through three key segments: Plasma, Blood Center, and Hospital.
In the Plasma segment, Haemonetics focuses on providing innovative technologies for plasma collection and processing. The company's products help ensure a steady supply of high-quality plasma for the production of biopharmaceuticals and other therapeutic applications.
Within the Blood Center segment, Haemonetics offers advanced solutions for blood component collection and processing, aiding in the optimization of blood supply chains. Despite facing high competition in this segment, the company continues to innovate and enhance its product offerings.
The Hospital segment is a significant growth area for Haemonetics, providing essential tools for surgical suites and transfusion services. The company's technologies help prevent unnecessary blood transfusions and ensure the right blood product is used at the right time, improving patient outcomes.
Recently, Haemonetics has achieved several milestones, including the acquisition of Attune Medical, the manufacturer of the FDA-cleared ensoETM® esophageal cooling device. This acquisition strengthens Haemonetics' presence in the electrophysiology market and complements its vascular closure offerings.
Haemonetics also received 510(k) clearance from the U.S. FDA for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge, expanding its capabilities to serve fully heparinized patients in critical surgical procedures.
The company's financial performance remains robust, with a strong focus on revenue growth and strategic investments. Haemonetics continues to explore new markets and develop cutting-edge technologies to stay at the forefront of the healthcare industry.
To stay updated with the latest developments and financial results, Haemonetics regularly hosts investor calls and webcasts, providing transparency and insights into its ongoing projects and future plans.
Haemonetics Corporation (NYSE: HAE) announced the availability of its third-quarter fiscal 2021 financial results, concluding on December 26, 2020. A conference call is scheduled for February 2, 2021, at 8:00 a.m. ET, to discuss the results and address investor queries. The earnings release, analytical tables, and details regarding the acquisition of Cardiva Medical, Inc. have been posted on the Investor Relations website. The company's innovative healthcare solutions aim to enhance patient care while reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) supports the FDA's new guidance on viscoelastic testing during the COVID-19 pandemic. The company is modifying labeling for its TEG® 5000 and TEG® 6s hemostasis analyzers to enhance patient care. These analyzers provide critical insights into blood clotting, addressing coagulopathy associated with COVID-19, which can lead to severe complications. Haemonetics aims to optimize blood resource utilization while ensuring that healthcare professionals have access to necessary technologies during this crisis.
Haemonetics (NYSE: HAE) has announced a definitive agreement to acquire Cardiva Medical for $475 million upfront, plus $35 million contingent on sales growth. This strategic acquisition aims to enhance Haemonetics' offerings in interventional cardiology and electrophysiology markets. The deal is expected to generate $65-$75 million in revenue in its first fiscal year but may dilute adjusted net earnings by $0.15 to $0.20 in fiscal 2022. The acquisition is projected to break even on earnings by fiscal 2023 and deliver a 10% return on invested capital by year five.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2021 financial results on February 2, 2021, at 6:00 am EDT. Following this, a conference call for investors and analysts will occur at 8:00 am EDT on the same day to discuss the results. Access to the call is available via toll-free and international numbers, with a conference ID required. A live webcast will also be available on Haemonetics' investor relations website, with a replay accessible from February 2 to February 10, 2021.
Haemonetics Corporation (NYSE:HAE) has released its financial results for the second quarter of fiscal 2021, concluding on September 26, 2020. The earnings release and results tables are accessible on its Investor Relations website, along with a scheduled conference call for investors on November 4, 2020, at 8 a.m. EST. Key financial metrics and strategic updates are expected to be discussed during this call. Investors can also view the live webcast for detailed insights into the company's performance.
Haemonetics Corporation (NYSE: HAE) announced the upcoming release of its second quarter fiscal year 2021 financial results, scheduled for November 4, 2020, at 6:00 am EDT. Following the announcement, the Company will host a conference call at 8:00 am EDT to discuss the results and address investor inquiries. The call can be accessed via a toll-free number or through a live webcast on Haemonetics' investor relations website. A replay of the webcast will be available from November 4 to November 12, 2020.
On October 2, 2020, Haemonetics Corporation (NYSE: HAE) announced FDA 510(k) clearance for its NexSys PCS® system with Persona™ technology. This innovative system customizes plasma collection based on individual donor body composition. Results from the IMPACT study showed an 8.2% increase in collected plasma volume. Persona technology optimizes collection for donors based on BMI and hematocrit.
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on September 15, 2020, at 9:30 a.m. ET. The presentation will be accessible to the public via a live webcast and subsequent replay.
Haemonetics specializes in innovative hematology products aimed at enhancing patient care and reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) announced that results from its IMPACT study will be presented at the AABB Annual Meeting on October 4, 2020. The study, involving 3,443 donors and 23,137 plasma donations, tested a novel, personalized approach to plasma collection using the NexSys PCS® Plasma Collection System. The findings indicated an 8.2% increase in plasma volume collected per donation while maintaining a safe profile. This innovation addresses the growing demand for plasma-derived therapies, with the NexSys PCS device pending FDA approval.
Haemonetics Corporation (NYSE:HAE) announced its financial results for the first quarter of fiscal 2021, ending June 27, 2020. The detailed earnings release and results tables are now available on their Investor Relations website. The company will host a conference call for investors and analysts on August 4, 2020, at 8 a.m. EDT to discuss the results. Interested parties can access the call using a toll-free number or via a live webcast. For additional information, visit Haemonetics' official website.
FAQ
What is the current stock price of Haemonetics Corporation (HAE)?
What is the market cap of Haemonetics Corporation (HAE)?
What does Haemonetics Corporation specialize in?
What are the main segments of Haemonetics' business?
What recent acquisitions has Haemonetics made?
What is the TEG® 6s hemostasis analyzer system?
How does Haemonetics support its plasma segment?
What are the financial highlights of Haemonetics?
How does Haemonetics improve patient care?
What was the significance of the FDA clearance for Haemonetics?
What is Haemonetics' approach to innovation?
How can investors stay updated on Haemonetics' performance?
